Letter

Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'

Sylvain Mathieu1,2*, Sylvain Palat2,3, Bruno Pereira2,4, Jean-Louis Kemeny2,5, Geoffroy Marceau2,6, Claude Dubray2,7 and Martin Soubrier1,2

Author Affiliations

1 Rheumatology Department, Gabriel Montpied Teaching Hospital, Place H. Dunant, Clermont-Ferrand 63000, France

2 Université Clermont 1, Fac Médecine, F-63003 Clermont-Ferrand, France

3 Service de Médecine Interne, Gabriel Montpied Teaching Hospital, Place H. Dunant, Clermont-Ferrand 63000, France

4 DRCI, Gabriel Montpied Teaching Hospital, Place H. Dunant, Clermont-Ferrand 63000, France

5 Laboratoire d'Anatomopathologie, Gabriel Montpied Teaching Hospital, Place H. Dunant, Clermont-Ferrand 63000, France

6 Laboratoire de Biochimie, Gabriel Montpied Teaching Hospital, Place H. Dunant, Clermont-Ferrand 63000, France

7 Centre d'Investigation Clinique, CHU G Montpied, F-63003 Clermont-Ferrand, France

For all author emails, please log on.

Arthritis Research & Therapy 2013, 15:402 doi:10.1186/ar4169


See related research by Vandebriel et al., http://arthritis-research.com/content/14/2/R90, and related letter by Vandebriel et al., http://arthritis-research.com/content/15/2/403

Published: 8 March 2013

First paragraph (this article has no abstract)

Statins used to treat hyperlipidemia also exhibit immune-modulatory properties. What is still unclear and a matter of debate, however, is whether these properties are of benefit or are deleterious in collagen type II-induced arthritis (CIA).